Skip to main content

Table 2 Characteristics of patients treated with G/P, who did not achieve sustained virological response

From: Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older

No.

Age

Gender

GT

Liver status

History of HCC

Prior HCV treatment

HCV RNA (log10IU/mL)

NS5A RAS

Treatment duration (weeks)

Outcome

1

71

F

1

CH

None

Peg-IFN/SMV/RBV

DCV/ASV

5.8

P32 deletion/Q54H

12

Relapse

2

75

F

2a

CH

None

None

6.5

Unmeasured

8

Relapse

3

70

F

2

CH

None

SOF/RBV

6.2

S62S/N/T/Y

7

Non-response

  1. F, female; GT, genotype; CH, chronic hepatitis; SMV, simeprevir; RBV, ribavirin; DCV, daclatasvir; ASV, asunaprevir; SOF, sofosbuvir